Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Growth hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    573 result(s) found for: Growth hormone. Displaying page 7 of 29.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2009-010787-42 Sponsor Protocol Number: 2-55-52060-003 Start Date*: 2009-09-02
    Sponsor Name:Ipsen Pharma
    Full Title: PHASE II, OPEN, RANDOMISED, PARALLEL GROUP, NONCOMPARATIVE MULTICENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPEATED SUBCUTANEOUS (S.C.) ADMINISTRATION OF DIFFERENT DOSES OF BIM 23A760 IN ACR...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended) LV (Prematurely Ended) DE (Completed) FR (Completed) LT (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003496-20 Sponsor Protocol Number: LAR/005 Start Date*: 2006-10-31
    Sponsor Name:Oxford Radcliffe Hospitals NHS trust
    Full Title: The effect of pre-operative Octreotide LAR treatment on surgical cure rates of subjects with Acromegaly, and post-operative responsiveness to somatostatin analogue treatment in patients not cured s...
    Medical condition: Acromegaly, overproduction of growth hormone by (almost always) a benign pituitary tumour.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001658-25 Sponsor Protocol Number: A6391002 Start Date*: 2005-06-16
    Sponsor Name:Pfizer Global Research and Development
    Full Title: An open label, two period crossover study to explore the safety, pharmacokinetics and pharmacodynamics of PHA-794428 after single subcutaneous injections in adult male patients with growth hormone ...
    Medical condition: AGHD Adult Growth Hormone Deficiency
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018586-39 Sponsor Protocol Number: 2010/0121 Start Date*: 2010-06-01
    Sponsor Name:Medical Department M (Endocrinology & Diabetes)
    Full Title: Diurnal variation of exogenous peptides
    Medical condition: Adults with growth hormone disease (AGHD).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000675-20 Sponsor Protocol Number: ISIS766720-CS5 Start Date*: 2020-11-04
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherap...
    Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) PL (Completed) LV (Prematurely Ended) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-005585-12 Sponsor Protocol Number: 1 Start Date*: 2007-12-20
    Sponsor Name:Department of Internal Medicine of the University of Munich
    Full Title: Prospektive, offene Studie zur Prüfung der Wirksamkeit der zusätzlichen Gabe des Somatostatinanalogon Octreotid (Sandostatin) bzw. des Dopaminagonisten Cabergolin (Dostinex) bei Patientin mit Akrom...
    Medical condition: acromegaly (= growth hormone hypersecretion mostly caused by a pituitary adenoma)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002164-41 Sponsor Protocol Number: END-GH-2017 Start Date*: 2017-07-03
    Sponsor Name:Fundació Parc Taulí
    Full Title: Growth hormone therapy in adults with Prader-Willi syndrome: Effect on muscle tone assessed by functional magnetic resonance imaging (fMRI) and its relation to muscle strenght and body composition.
    Medical condition: Patients with Prader-Willi Syndrome (SPW) with Growth hormone deficit.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005431-70 Sponsor Protocol Number: CRN00808-09 Start Date*: 2022-03-04
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) AT (Completed) DE (Completed) HU (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) ES (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023674-39 Sponsor Protocol Number: AKRO1 Start Date*: 2014-08-05
    Sponsor Name:Österreichisches Akromegalie Register
    Full Title: Evaluation of a standardized treatment regimen for acromegaly: A multi centre intervention study
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    17.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003104-11 Sponsor Protocol Number: 1.0 Start Date*: 2005-10-11
    Sponsor Name:Fertility clinic Odense University Hospital
    Full Title: Androgen priming in the late luteal phase as a mean to improve the outcome of ovarian stimulation for IVF in normogonadotrophic women with a previously proven poor response
    Medical condition: Hypothesis. By combining pituitary downregulation with aromatase inhibitor, and hCG injection during a late luteal phase a powerful stimulation of thecal androgen production is achieved. Thereby, i...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003099-39 Sponsor Protocol Number: LWH0604 Start Date*: 2008-08-21
    Sponsor Name:Liverpool Women's NHS Foundation Trust Hospital
    Full Title: A Randomised Controlled Trial of Thyroxine in Preterm Infants Under 28 weeks' Gestation.
    Medical condition: Hypothyroidism is a condition where there is a lack of thyroid hormone in the body. Thyroid hormones are important for normal brain development and growth. Children who are born with low thyroid ho...
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000500-83 Sponsor Protocol Number: 2-55-52060-002 Start Date*: 2008-07-15
    Sponsor Name:Ipsen Pharma
    Full Title: A phase II exploratory, ascending dose, multicentre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability, of BIM23A760 in acromegalic patients.
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BE (Completed) IT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2014-004105-32 Sponsor Protocol Number: 307-MET-9002-052 Start Date*: 2015-04-01
    Sponsor Name:Pfizer Inc
    Full Title: Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor (Genotonorm) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-Term Corticosteroid T...
    Medical condition: Juvenile idiopathic arthritis (JIA)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-010918-30 Sponsor Protocol Number: 2377 Start Date*: 2009-08-11
    Sponsor Name:Amar Agha, Beaumont Hospital
    Full Title: Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism.
    Medical condition: 20 patients with hypopituitarism including growth hormone deficiency will be evaluated both on growth hormone replacement and when they have been off it for a 2 month period. They will have been pr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021067 Hypopituitarism LLT
    9.1 10033662 Panhypopituitarism LLT
    9.1 10056438 Growth hormone deficiency LLT
    9.1 10011318 Craniopharyngioma LLT
    9.1 10036832 Prolactinoma LLT
    9.1 10011651 Cushing's disease LLT
    9.1 10035104 Pituitary tumour LLT
    9.1 10061538 Pituitary tumour benign LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000232-10 Sponsor Protocol Number: NN8640-4245 Start Date*: 2019-05-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: A dose-finding trial evaluating the effect and safety of once-weekly treatment of somapacitan compared to daily Norditropin® in children with short stature born small for gestational age with no ca...
    Medical condition: Short stature in children born small for gestational age with no catch-up growth by 2 years of age or older
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004868 10041093 Small for gestational age LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) NO (Ongoing) IE (Completed) EE (Completed) HU (Trial now transitioned) LV (Trial now transitioned) PL (Completed) ES (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005240-10 Sponsor Protocol Number: C/24/2011 Start Date*: 2012-03-27
    Sponsor Name:Imperial College London
    Full Title: A phase II, open label, preoperative study to assess the efficacy of the novel steroid sulfatase inhibitor Irosustat in postmenopausal women with early oestrogen receptor positive breast cancer.
    Medical condition: Breast Cancer, ER positive, early
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001292-51 Sponsor Protocol Number: CH-ACM-01-FU Start Date*: 2015-06-30
    Sponsor Name:Chiasma, Inc.
    Full Title: Follow-Up Study in Patients with Acromegaly Previously Participating in Chiasma Study CH-ACM-01
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SI (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003575-11 Sponsor Protocol Number: VitaminD&TT Start Date*: 2013-03-05
    Sponsor Name:Medizinische Universität Graz, Innere Medizin
    Full Title: A randomized, double-blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on androgen levels in hypogonadal men
    Medical condition: Male hypogonadism (total testosterone <3ng/ml)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10000193 Male sex hormone abnormalities HLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000591-42 Sponsor Protocol Number: ISIS766720-CS3 Start Date*: 2019-06-14
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open-Label Extension Trial of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor Administered Monthly Subcutaneously to Patients with Acromegaly Being Treated with Long-Acting ...
    Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) PL (Completed) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005838-37 Sponsor Protocol Number: A-38-52030-214 Start Date*: 2008-05-15
    Sponsor Name:Beaufour Ipsen Pharma
    Full Title: A PROSPECTIVE, INTERNATIONAL, MULTI-CENTRIC, OPEN-LABEL STUDY TO ASSESS THE EFFICACY OF AN EXTENDED INJECTION INTERVAL SCHEDULE OF LANREOTIDE AUTOGEL 120 MG IN ACROMEGALIC SUBJECTS WHO ARE BIOCHEMI...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) DK (Completed) NL (Completed) FI (Completed) LV (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 09:29:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA